Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AnaptysBio raises $40m for Phase II studies

This article was originally published in Scrip

Executive Summary

San Diego-based AnaptysBio has several antibody discovery partnerships with pharmaceutical and biotechnology companies, but the firm will use its $40m in Series D venture capital financing to run Phase II clinical trials for two of its own therapeutic candidates.

You may also be interested in...



IPO Update: Three Biopharma Offerings In January Contrast With Last Year’s Slow Start

AnaptysBio, Jounce and ObsEva were the first three companies to go public in 2017 – all in January – while no therapeutics firms went public in January 2016. The difference? Better US biopharma stock performance.

Alzheimer’s Experts: Lecanemab Is A Win, But Also Just The Beginning

While Phase III results for Eisai and Biogen’s lecanemab show amyloid clearance provides benefit and Roche’s Phase III gantenerumab data are supportive, more data and certainty of access to treatment are needed.

How Much Amyloid Clearance, How Fast Is Needed To Slow Alzheimer’s?

Lilly’s donanemab showed faster, deeper amyloid clearance versus Biogen/Eisai’s Aduhelm and Roche’s failed Phase III gantenerumab studies showed the importance of deep, rapid removal.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC029239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel